Top

Published in:

Open Access 01-12-2010 | Review

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

Authors: Christophe Frémin, Sylvain Meloche

Published in: Journal of Hematology & Oncology | Issue 1/2010

Abstract

The Ras-dependent Raf/MEK/ERK1/2 mitogen-activated protein (MAP) kinase signaling pathway is a major regulator of cell proliferation and survival. Not surprisingly, hyperactivation of this pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine kinases or gain-of-function mutations in RAS or RAF genes. Components of the ERK1/2 pathway are therefore viewed as attractive candidates for the development of targeted therapies of cancer. In this article, we briefly review the basic research that has laid the groundwork for the clinical development of small molecules inhibitors of the ERK1/2 pathway. We then present the current state of clinical evaluation of MEK1/2 inhibitors in cancer and discuss challenges ahead.

Available only for authorised users

Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.PubMedCrossRef

Ray LB, Sturgill TW: Characterization of insulin-stimulated microtubule-associated protein kinase. Rapid isolation and stabilization of a novel serine/threonine kinase from 3T3-L1 cells. J Biol Chem. 1988, 263: 12721-12727.PubMed

Raman M, Chen W, Cobb MH: Differential regulation and properties of MAPKs. Oncogene. 2007, 26: 3100-3112. 10.1038/sj.onc.1210392.PubMedCrossRef

Yoon S, Seger R: The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006, 24: 21-44. 10.1080/02699050500284218.PubMedCrossRef

Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001, 22: 153-183. 10.1210/er.22.2.153.PubMed

Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ: Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003, 17: 1969-1978. 10.1101/gad.1107303.PubMedCentralPubMedCrossRef

Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, Labow MA, Zon LI: SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci USA. 1998, 95: 6881-6886. 10.1073/pnas.95.12.6881.PubMedCentralPubMedCrossRef

Fukuda M, Gotoh I, Gotoh Y, Nishida E: Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. J Biol Chem. 1996, 271: 20024-20028. 10.1074/jbc.271.33.20024.PubMedCrossRef

Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R: Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol. 2007, 27: 803-817. 10.1128/MCB.00601-06.PubMedCentralPubMedCrossRef

10.

Eblen ST, Slack JK, Weber MJ, Catling AD: Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol Cell Biol. 2002, 22: 6023-6033. 10.1128/MCB.22.17.6023-6033.2002.PubMedCentralPubMedCrossRef

11.

Wu X, Noh SJ, Zhou G, Dixon JE, Guan KL: Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J Biol Chem. 1996, 271: 3265-3271. 10.1074/jbc.271.6.3265.PubMedCrossRef

12.

Xu S, Khoo S, Dang A, Witt S, Do V, Zhen E, Schaefer EM, Cobb MH: Differential regulation of mitogen-activated protein/ERK kinase (MEK)1 and MEK2 and activation by a Ras-independent mechanism. Mol Endocrinol. 1997, 11: 1618-1625. 10.1210/me.11.11.1618.PubMedCrossRef

13.

Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, Carugo O, Baccarini M: A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol. 2009, 16: 294-303. 10.1038/nsmb.1564.PubMedCrossRef

14.

Scholl FA, Dumesic PA, Khavari PA: Mek1 alters epidermal growth and differentiation. Cancer Res. 2004, 64: 6035-6040. 10.1158/0008-5472.CAN-04-0017.PubMedCrossRef

15.

Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK, Rodrigue-Gervais IG, Gaboury L, Lamarre D, Basik M: Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer. 2008, 8: 337-10.1186/1471-2407-8-337.PubMedCentralPubMedCrossRef

16.

Scholl FA, Dumesic PA, Barragan DI, Charron J, Khavari PA: Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin. Oncogene. 2009, 28: 1485-1495. 10.1038/onc.2008.459.PubMedCentralPubMedCrossRef

17.

Mody N, Leitch J, Armstrong C, Dixon J, Cohen P: Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 2001, 502: 21-24. 10.1016/S0014-5793(01)02651-5.PubMedCrossRef

18.

Kamakura S, Moriguchi T, Nishida E: Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem. 1999, 274: 26563-26571. 10.1074/jbc.274.37.26563.PubMedCrossRef

19.

Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004, 11: 1192-1197. 10.1038/nsmb859.PubMedCrossRef

20.

Meloche S, Pouyssegur J: The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007, 26: 3227-3239. 10.1038/sj.onc.1210414.PubMedCrossRef

21.

Meloche S, Seuwen K, Pages G, Pouyssegur J: Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol. 1992, 6: 845-854. 10.1210/me.6.5.845.PubMed

22.

Jones SM, Kazlauskas A: Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol. 2001, 3: 165-172. 10.1038/35055073.PubMedCrossRef

23.

Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E: Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr Biol. 2006, 16: 1171-1182. 10.1016/j.cub.2006.04.044.PubMedCrossRef

24.

Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA. 1993, 90: 8319-8323. 10.1073/pnas.90.18.8319.PubMedCentralPubMedCrossRef

25.

Liu X, Yan S, Zhou T, Terada Y, Erikson RL: The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene. 2004, 23: 763-776. 10.1038/sj.onc.1207188.PubMedCrossRef

26.

Fremin C, Ezan F, Boisselier P, Bessard A, Pages G, Pouyssegur J, Baffet G: ERK2 but not ERK1 plays a key role in hepatocyte replication: An RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes. Hepatology. 2007, 45: 1035-1045. 10.1002/hep.21551.PubMedCrossRef

27.

Lefloch R, Pouyssegur J, Lenormand P: Single and combined ERK1/ERK2 silencing reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol. 2007

28.

Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 1995, 92: 7686-7689. 10.1073/pnas.92.17.7686.PubMedCentralPubMedCrossRef

29.

DeSilva DR, Jones EA, Favata MF, Jaffee BD, Magolda RL, Trzaskos JM, Scherle PA: Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol. 1998, 160: 4175-4181.PubMed

30.

Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999, 5: 810-816. 10.1038/10533.PubMedCrossRef

31.

Brunet A, Pages G, Pouyssegur J: Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene. 1994, 9: 3379-3387.PubMed

32.

Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 1994, 77: 841-852. 10.1016/0092-8674(94)90133-3.PubMedCrossRef

33.

Seger R, Seger D, Reszka AA, Munar ES, Eldar-Finkelman H, Dobrowolska G, Jensen AM, Campbell JS, Fischer EH, Krebs EG: Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. J Biol Chem. 1994, 269: 25699-25709.PubMed

34.

Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F, Auberger P, Pouyssegur J: Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science. 1999, 286: 1374-1377. 10.1126/science.286.5443.1374.PubMedCrossRef

35.

Saba-El-Leil MK, Vella FD, Vernay B, Voisin L, Chen L, Labrecque N, Ang SL, Meloche S: An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep. 2003, 4: 964-968. 10.1038/sj.embor.embor939.PubMedCentralPubMedCrossRef

36.

Samuels IS, Karlo JC, Faruzzi AN, Pickering K, Herrup K, Sweatt JD, Saitta SC, Landreth GE: Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci. 2008, 28: 6983-6995. 10.1523/JNEUROSCI.0679-08.2008.PubMedCentralPubMedCrossRef

37.

D'Souza WN, Chang CF, Fischer AM, Li M, Hedrick SM: The Erk2 MAPK regulates CD8 T cell proliferation and survival. J Immunol. 2008, 181: 7617-7629.PubMedCentralPubMedCrossRef

38.

Roovers K, Assoian RK: Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays. 2000, 22: 818-826. 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6.PubMedCrossRef

39.

Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J: Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996, 271: 20608-20616. 10.1074/jbc.271.34.20608.PubMedCrossRef

40.

Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000, 14: 2501-2514. 10.1101/gad.836800.PubMedCentralPubMedCrossRef

41.

Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC: ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008, 10: 138-148. 10.1038/ncb1676.PubMedCentralPubMedCrossRef

42.

Hwang CY, Lee C, Kwon KS: Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol. 2009, 29: 3379-3389. 10.1128/MCB.01758-08.PubMedCentralPubMedCrossRef

43.

Chambard JC, Lefloch R, Pouyssegur J, Lenormand P: ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007, 1773: 1299-1310. 10.1016/j.bbamcr.2006.11.010.PubMedCrossRef

44.

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA. 2004, 101: 13489-13494. 10.1073/pnas.0405659101.PubMedCentralPubMedCrossRef

45.

Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005, 121: 179-193. 10.1016/j.cell.2005.02.031.PubMedCrossRef

46.

Ballif BA, Blenis J: Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 2001, 12: 397-408.PubMed

47.

Balmanno K, Cook SJ: Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009, 16: 368-377. 10.1038/cdd.2008.148.PubMedCrossRef

48.

Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995, 270: 1326-1331. 10.1126/science.270.5240.1326.PubMedCrossRef

49.

Parrizas M, Saltiel AR, LeRoith D: Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997, 272: 154-161. 10.1074/jbc.272.1.154.PubMedCrossRef

50.

Erhardt P, Schremser EJ, Cooper GM: B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol. 1999, 19: 5308-5315.PubMedCentralPubMedCrossRef

51.

Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E: The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell. 2000, 11: 1103-1112.PubMedCentralPubMedCrossRef

52.

Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouyssegur J: MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004, 109: 1938-1941. 10.1161/01.CIR.0000127126.73759.23.PubMedCrossRef

53.

Scholl FA, Dumesic PA, Barragan DI, Harada K, Bissonauth V, Charron J, Khavari PA: Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell. 2007, 12: 615-629. 10.1016/j.devcel.2007.03.009.PubMedCrossRef

54.

Grandis JR, Sok JC: Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004, 102: 37-46. 10.1016/j.pharmthera.2004.01.002.PubMedCrossRef

55.

Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-354. 10.1038/nrc1609.PubMedCrossRef

56.

Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007, 7: 295-308. 10.1038/nrc2109.PubMedCrossRef

57.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W: Mutations of the BRAF gene in human cancer. Nature. 2002, 417: 949-954. 10.1038/nature00766.PubMedCrossRef

58.

Garnett MJ, Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004, 6: 313-319. 10.1016/j.ccr.2004.09.022.PubMedCrossRef

59.

Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D: Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008, 68: 5524-5528. 10.1158/0008-5472.CAN-08-0099.PubMedCentralPubMedCrossRef

60.

Murugan AK, Dong J, Xie J, Xing M: MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle. 2009, 8: 2122-2124.PubMedCrossRef

61.

Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999, 18: 813-822. 10.1038/sj.onc.1202367.PubMedCrossRef

62.

Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004, 4: 937-947. 10.1038/nrc1503.PubMedCrossRef

63.

Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Woude Vande GF, Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994, 265: 966-970. 10.1126/science.8052857.PubMedCrossRef

64.

Pinkas J, Leder P: MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. Cancer Res. 2002, 62: 4781-4790.PubMed

65.

Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, Tzivion G: Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta. 2007, 1773: 1196-1212. 10.1016/j.bbamcr.2007.05.001.PubMedCentralPubMedCrossRef

66.

Hobbs RM, Silva-Vargas V, Groves R, Watt FM: Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol. 2004, 123: 503-515. 10.1111/j.0022-202X.2004.23225.x.PubMedCrossRef

67.

Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG: Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene. 2009, 28: 2289-2298. 10.1038/onc.2009.95.PubMedCentralPubMedCrossRef

68.

Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA: Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005, 65: 4238-4245. 10.1158/0008-5472.CAN-05-0047.PubMedCrossRef

69.

Jeong JH, Wang Z, Guimaraes AS, Ouyang X, Figueiredo JL, Ding Z, Jiang S, Guney I, Kang GH, Shin E: BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One. 2008, 3: e3949-10.1371/journal.pone.0003949.PubMedCentralPubMedCrossRef

70.

Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y: Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007, 67: 4933-4939. 10.1158/0008-5472.CAN-06-4592.PubMedCrossRef

71.

Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M: Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001, 108: 851-859.PubMedCentralPubMedCrossRef

72.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I: BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006, 439: 358-362. 10.1038/nature04304.PubMedCentralPubMedCrossRef

73.

Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS: Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res. 2003, 63: 5669-5673.PubMed

74.

Kramer BW, Gotz R, Rapp UR: Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer. 2004, 4: 24-10.1186/1471-2407-4-24.PubMedCentralPubMedCrossRef

75.

Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995, 270: 27489-27494. 10.1074/jbc.270.46.27489.PubMedCrossRef

76.

Servant MJ, Giasson E, Meloche S: Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. J Biol Chem. 1996, 271: 16047-16052. 10.1074/jbc.271.27.16047.PubMedCrossRef

77.

Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998, 273: 18623-18632. 10.1074/jbc.273.29.18623.PubMedCrossRef

78.

Williams DH, Wilkinson SE, Purton T, Lamont A, Flotow H, Murray EJ: Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. Biochemistry. 1998, 37: 9579-9585. 10.1021/bi972914c.PubMedCrossRef

79.

Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005, 23: 5281-5293. 10.1200/JCO.2005.14.415.PubMedCrossRef

80.

Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP: Multicenter phase II study of the oral MEK inhibitor, CI- in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 1040, 22: 4456-4462. 10.1200/JCO.2004.01.185.CrossRef

81.

Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR: The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008, 18: 6501-6504. 10.1016/j.bmcl.2008.10.054.PubMedCrossRef

82.

Lorusso P, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G, Varterasian M, Sadis SS, Menon SS, Leopold J, Meyer MB: A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol (abstract). 2005, 23: 3011-

83.

Menon SS, Whitfield LR, Sadis S, Meyer MB, Leopold J, Lorusso PM, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G: Pharmacokinetics (PK) and pharmacodynamics (PD) of PD0325901, a second generation MEK inhibitor after multiple oral doses of PD0325901 to advanced cancer patients. J Clin Oncol (abstract). 2005, 23: 3066-

84.

Wang D, Boerner SA, Winkler JD, LoRusso PM: Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta. 2007, 1773: 1248-1255. 10.1016/j.bbamcr.2006.11.009.PubMedCrossRef

85.

Lorusso P, Krishnamurthi S, Rinehart J, Nabell L, Croghan G, Chapman P, Selaru P, Kim S, Ricart A, Wliner K: Clinical aspects of a phase I study of PD032 a selective oral MEK inhibitor, in patients with advanced cancer. Mol Cancer Ther (abstract B113). 5901, 6: 3646s-

86.

Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S: Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor. Clin Cancer Res. 2007, 13: 1576-1583. 10.1158/1078-0432.CCR-06-1150.PubMedCrossRef

87.

Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD: AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007, 6: 2209-2219. 10.1158/1535-7163.MCT-07-0231.PubMedCrossRef

88.

Huynh H, Soo KC, Chow PK, Tran E: Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007, 6: 138-146. 10.1158/1535-7163.MCT-06-0436.PubMedCrossRef

89.

Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS: The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res. 2008, 14: 230-239. 10.1158/1078-0432.CCR-07-1440.PubMedCrossRef

90.

Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008, 26: 2139-2146. 10.1200/JCO.2007.14.4956.PubMedCentralPubMedCrossRef

91.

Drummer R, Robert C, Chapman P, Sosman J, Middleton M, Bastholt L, Kemsley K, Cantarini M, Morris C, Kirkwood J: AZD6244 (ARRY-142886) vs Temozolomide in Patients With Advanced Melanoma: an Open-Label, Randomized, Multicenter, Phase II Study. J Clin Oncol (abstract). 2008, 26: 9033-

92.

Tzekova V, Cebotaru C, Ciuleanu TE, Damjanov D, Ganchev V, Kanarev V, Stella PJ, Sanders N, Pover G, Hainsworth JD: Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (abstract). 2008, 26: 8029-

93.

Lang I, Adenis A, Boer K, Escudero P, Kim T, Valladares M, Sanders N, Pover G, Douillard JY: AZD6244 (ARRY-142886) Versus Capecitabine in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Chemotherapy. J Clin Oncol (abstract). 2008, 26: 4114-

94.

O'Neil BH, Williams-Goff LW, Kauh J, Bekaii-Saab T, Strosberg JR, Lee R, Deal AM, Sullivan D, Sebti SM: A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol (abstract). 2009, 27: 15574-

95.

Johnston S: XL518, a potent, selective orally bioavailable MEK1 inhibitor, down-regulates the Ras/Raf/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in preclinical models. 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2007, Abstract C209

96.

Rosen LS, Galatin P, Fehling JM, Laux I, Dinolfo M, Frye J, Laird D, Sikic BI: A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. J Clin Oncol (abstract). 2008, 26: 14585-

97.

Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM: RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009, 69: 6839-6847. 10.1158/0008-5472.CAN-09-0679.PubMedCrossRef

98.

Thompson D, Flaherty K, Messersmith W, Harlacker K, Nallapareddy S, Vincent C, DeMarini D, Cox D, O'Neill V, Burris H: A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administred orally with solid tumors or lymphoma. J Clin Oncol (abstract). 2009, 27: e14584-

99.

Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, Moliterni J, Huby N, Fotouhi N, Liu M: Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models. Mol Cancer Ther. 2010, 9: 134-144. 10.1158/1535-7163.MCT-09-0601.PubMedCrossRef

100.

Daouti S, Wang H, Li WH, Higgins B, Kolinsky K, Packman K, Specian A, Kong N, Huby N, Wen Y: Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy. Cancer Res. 2009, 69: 1924-1932. 10.1158/0008-5472.CAN-08-2627.PubMedCrossRef

101.

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006, 5: 835-844. 10.1038/nrd2130.PubMedCrossRef

102.

Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F: PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69: 4286-4293. 10.1158/0008-5472.CAN-08-4765.PubMedCrossRef

103.

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008, 14: 1351-1356. 10.1038/nm.1890.PubMedCentralPubMedCrossRef

104.

Nature Journal. [http://www.nature.com/news/2009/090602/full/news.2009.536.html]

105.

Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009, 106: 20411-20416. 10.1073/pnas.0905833106.PubMedCentralPubMedCrossRef

Title: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Authors: Christophe Frémin
Sylvain Meloche
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2010
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-3-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Sweet fruit from a poisonous kiss

Mitochondrial and endoplasmic reticulum stress pathways cooperate in zearalenone-induced apoptosis of human leukemic cells

Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology

Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report

Keynote webinar | Spotlight on antibody–drug conjugates in cancer